Long-term follow up of patients affected by pulmonary carcinoid at the Istituto Nazionale Tumori of Milan: a retrospective analysis.

Sara Pusceddu(Fondazione IRCCS Istituto Nazionale dei Tumori), Emilio Bajetta(Fondazione Lanza), Alessandra Fabbri(Universidade de São Paulo), Laura Catena(Fondazione IRCCS Istituto Nazionale dei Tumori), Roberto Buzzoni(Fondazione IRCCS Istituto Nazionale dei Tumori), Luca Tavecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Barbara Formisano(Fondazione IRCCS Istituto Nazionale dei Tumori), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), Monica Valente(University of Siena), Monika Ducceschi(Fondazione IRCCS Istituto Nazionale dei Tumori)
PubMed
March 1, 2010
Cited by 16

Related Papers

Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
|New England Journal of Medicine|2017|2.2k
A Randomized Trial of Exemestane after Two to Three Years of Tamoxifen Therapy in Postmenopausal Women with Primary Breast Cancer
|New England Journal of Medicine|2004|1.8k
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
|The Lancet|2009|1.4k
Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial
|The Lancet|2007|912
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial
|The Lancet Oncology|2017|780